JPRN-jRCT2080220236未知3 期
SPP100 (Aliskiren) regimen in patients with severe hypertension
ovartis Pharma K.K.0 个研究点目标入组 38 人开始时间: 2006年4月21日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •Inclusion criteria
- •- Age: 20-80 years old
- •- Gender: Male or female
- •- Status: Outpatients
- •- Severe hypertension
- •Exclusion criteria
- •- Patients with a clinically significant allergy
- •- Patients who have received other investigational drug
- •- Alcoholic patients
- •Other protocol-defined inclusion/exclusion criteria may apply
排除标准
- 未提供
研究者
相似试验
未知
Unknown
A long term study of SPP100 in patients with essential hypertensioHypertensionJPRN-jRCT2080220180ovartis Pharma K.K.300
未知
2 期
Phase IIa Study of S-555739 in Patients with Perennial Allergic RhinitisPerennial allergic rhinitisJPRN-jRCT2080220844SHIONOGI & CO., LTD.
进行中（未招募）
不适用
Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT) - ASPIRANTEUCTR2007-003558-27-CZOlomouc University Hospital and Palacký University School of Medicine, Internal Medicine Dept. I160
已完成
1 期
A phase I study of SMP-105 (BCG-CWS) in patients with advanced cancers refractory to the standard treatmentMalignant tumorsJPRN-UMIN000008485Kobe Haborland Immunotherapy Clinic9
进行中（未招募）
不适用
Efficacy and safety of SAR407899A in patients with painful diabetic neuropathy. A 28-day, randomized, double-blind, placebo-controlled, parallel-group study.Diabetic peripheral neuropathic painMedDRA version: 12.0Level: LLTClassification code 10067547Term: Diabetic peripheral neuropathic painEUCTR2009-015066-61-ATSanofi-Aventis Recherche & Développement80